Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Clin Cancer Res. 2010 Jun 22;16(13):3399–3408. doi: 10.1158/1078-0432.CCR-09-3087

Figure 2.

Figure 2

Effect of CpG-ODN on CD8 and NK cells. Mice bearing four day-old intracranial GL261 tumors were treated with intratumoral CpG-ODN (3μg/injection), control ODN (3μg/injection), and PBS once (one inj.) or four (four inj.) times as described in Fig. 1. Twenty-four hr after the last injection, brain, spleen, and blood were harvested and analyzed by flow cytometry for the percentage of CD8 (top panel) and NK (bottom panel) cells. P values for significant differences between treatment groups are provided above each bar graph. Significant differences between one and four injections for each treatment is represented as *: p<0.05, **: p<0.001, ***: p<0.0001. n=4 mice for each treatment group. Data is representative of two separate experiments.